Business
OneSource Specialty Pharma Reports 37% Revenue Growth, 39% EBITDA Rise in Q1 FY27
By MILLENNIUM NEWSROOM Desk · Published: Jul 24, 2026 10:06 PM
2 min read
OneSource Specialty Pharma Limited (BSE: 544252, NSE: ONESOURCE) on Friday announced its consolidated financial results for the quarter ended June 30, 2026, reporting strong year-on-year growth in revenue and profitability, supported by the commercial launch of semaglutide, new master service agreement (MSA) contracts and customer additions across its businesses.
The company reported revenue of ₹4,490 million in the first quarter of FY27, representing a 37% year-on-year (YoY) increase and a 5% quarter-on-quarter (QoQ) rise from ₹4,282 million in Q4 FY26.
EBITDA Rises 39% as Margins Expand
OneSource posted an EBITDA of ₹1,233 million, up 39% YoY and 34% QoQ. EBITDA margins improved to 27.5%, compared with 27.0% in Q1 FY26 and 21.5% in the previous quarter, reflecting operating leverage from higher semaglutide revenues.
The company's Adjusted Profit After Tax (PAT) stood at ₹637 million, registering a 72% YoY increase and a 63% QoQ rise. Adjusted earnings per share (EPS) came in at ₹5.6, compared with ₹3.2 in Q1 FY26 and ₹3.4 in Q4 FY26.
Adjusted PAT and Adjusted EPS exclude exceptional items (Q1 FY27: ₹43 million, Q4 FY26: gain of ₹0.3 million, Q1 FY26: ₹25 million) and scheme-related intangible amortisation of ₹344 million in each quarter.
Key Financial Performance
| Particulars | Q1 FY27 | Q4 FY26 | QoQ | Q1 FY26 | YoY |
|---|---|---|---|---|---|
| Revenue (₹ million) | 4,490 | 4,282 | 5% | 3,273 | 37% |
| EBITDA (₹ million) | 1,233 | 919 | 34% | 885 | 39% |
| EBITDA Margin | 27.5% | 21.5% | +600 bps | 27.0% | +43 bps |
| Adjusted PAT (₹ million) | 637 | 390 | 63% | 371 | 72% |
| Adjusted EPS (₹) | 5.6 | 3.4 | 63% | 3.2 | 71% |
FY28 Outlook Remains Unchanged
The company reaffirmed its FY28 guidance, targeting US$400 million in organic revenue with an EBITDA margin of 40%, reflecting confidence in its long-term growth strategy and expanding manufacturing capabilities.
Management Commentary
"We have started FY27 on a strong note, delivering robust growth in revenue and EBITDA, driven by commercialisation of semaglutide in Canada and India. We are excited to bring our second cartridge line into commercial operations in Q2, a significant milestone in our capacity expansion. Our biologics business gathered further momentum this quarter with the addition of yet another leading global biosimilar customer, reinforcing the strength of our integrated CDMO capabilities," said Neeraj Sharma, CEO & Managing Director, OneSource Specialty Pharma Limited.
(Inputs from Press Release)